{"name":"Ajax Therapeutics, Inc.","slug":"ajax-therapeutics-inc","ticker":"","exchange":"","domain":"ajax.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AJ1-11095","genericName":"AJ1-11095","slug":"aj1-11095","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"AJ1-11095","genericName":"AJ1-11095","slug":"aj1-11095","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxOMTR4NzEwbDFpcTZNOWZvY1l4S2pEZnc5eUE5aEtWZkNjLWxKb2dtZUxNYU5JcnhVU2NUQTkwYnlOLWdLWFJuYXJoRUhGTTFFcmNkYXlYSDRmV29paVliOHNhRGRkMXY3T3BhaUpJNUZobjBuSTh1VFJrMlBRVmZ6WmxCN1cxci1Qc1hPMG1yNG5mOXZLSFFDVDc5OVhKbXJqbFhXLWEwS2dSU19nejdhNWFKeHBfbEE5WFYzU2xDT3hRV3dhc3Q2Z2J3eFpxc2cxT1dZQUE4MlhHYUt4eVRPSG12Z09lWHN3YU41UHFheGp5QnVNNkdWUXh6ZGNROWxDbVBJ?oc=5","date":"2026-03-23","type":"pipeline","source":"StreetInsider","summary":"JAK Inhibitor Therapeutic Pipeline Strengthens as 50+ Pharma Companies Advance Over 55 Drug Candidates | DelveInsight - StreetInsider","headline":"JAK Inhibitor Therapeutic Pipeline Strengthens as 50+ Pharma Companies Advance Over 55 Drug Candidates | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOVExJQ0tfMFJObmFMTkhzZ1FvYlFwN2VsVFN6bUQ5b3ZzOHBtd3VuUjE0Rjltc2M0emFHVG92TmRYUE1ZVmVqYW04ZVhuR1IyWHhSdXBKUGlnRnJldUdCbXUzYURucWRnbFR4SDZaajFmYXlyMUIxdmVieWRKdUtmM3RxOS1IMTgyb0V4bWt3Q1hNOXBpVmpudg?oc=5","date":"2026-03-20","type":"pipeline","source":"openPR.com","summary":"Myelofibrosis Pipeline 2026: Therapies Under Investigation, - openPR.com","headline":"Myelofibrosis Pipeline 2026: Therapies Under Investigation,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxQYzkxLTVrTkVEMEo2RFd3T0dHRjdrZUF5Q0YzZkxGcDNKQ00wUWJmR1Z2R2Rfa0dJWE43UGJ4ZWdTMURfOHdRdy16VHNmVTdnbWtkVlZHdkV5clctcUtBV0N5OERLUTJHaUR0NHU2c1gxWUtUOExQYlhwWmpXNDlLNTZSSEhQSXp0Z2t4SC0tTVdKaDZWbXJ5ZnMxaVBMcTFObVJudjBBZ1hNQkp1NjZNY2doQnlIWVBMemxRX250aDZjcUdXeWJSclZwN0tYV0NFNzZBSg?oc=5","date":"2026-01-13","type":"pipeline","source":"BioSpace","summary":"Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities - BioSpace","headline":"Schrödinger Provides Update on Progress Across the Business and Outlines 2026 Strategic Priorities","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNQVU4Vlo0RWdnV0F3UUc2Q2NVcDg3VW5RUDIwZmkwNVAzSjV1bFFKQTdKR0s2RlJXZFQ5WDFIdy15c3lDbmRqOWVBazduQ01KSXF5blZKbHBDYjFWb2hzTGxiRlBkclZPSTVZUjNLT3JKR1Ita193bHFOMWM0WDVNR3Q4UUx2amwtMGdDdmwwbU0tVEFVZU1Mbi05Z25IcE9kZXZMUmR4SllId3VROEhhVDZDR3dsRGw5VjBQdTctdzNRLVpSaFN2N1BtS3ZrMUVOcmZmOS15NDhkVkpncXBFS3BnN2ZKdDFONVVMTw?oc=5","date":"2025-08-19","type":"pipeline","source":"GlobeNewswire","summary":"Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC - GlobeNewswire","headline":"Ajax Therapeutics Appoints David Waller, PhD, as Senior Vice President and Head of CMC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOVTZzQ2MwNk8yOFFiV2tFQ2thdFdBakVzYjRvSjNJcGZYRkpQaW94NVZ5dEtxdG04Q0VZZ09uV0N2ZzUxdFRYUlNLRzVtYXplemZLdnNWN0YtSGMwWS1rSkFuSDE4Mzh3U21Ld3B0LVlvbnhrSWgzWkxKcWpCUXAtb01MQmNkNHFlSXhCNVBvRFlZZHByRDU1QVRlU09tVTI0cS1wdzFfd3lGQ1M4UVNQemJ1bnZldmpWaGV1eWt6cWhkN0VyV1h5Nkl6ZVhKN3UwZVBCNU5mNFR0d3laR0ZFOGg3Q3ZkdF9LQ09zRXFVSlBGVmFDSVdpZUxVNDR6UQ?oc=5","date":"2025-08-05","type":"pipeline","source":"PR Newswire","summary":"Vitiligo Market to Register Incremental Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire","headline":"Vitiligo Market to Register Incremental Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAJBVV95cUxQT0pkMkxEYXAzQmNNOEFLNkN1S1RaazBYUGdNS29VVjNDeXotZEpuUGRKSURyQi1LY1dhWGJvcnJ1d2s0VEw4ZUhSSDNCZTBmZzJxcWJrUkdycUpuV0lmOEFNakFpT2otaEcyLWZlX0F6cVV1Q0dxczZXY0VJbUYzVTFlR2dHYkExTXFzdnYxZ3ZlZWpBV2xSamFXcklJejNFQmhvQ2RTT2ZwLU9meXoxa1dGQ2ZwTzZZRHRzR1d4OFE4WXctVzFPWHBQZi1MYXl6NENOTGxmWG53eWdDYVUwM2lhQVBIM04zRnhfUVE1dVE0dG5WUnNzaTF4X2hyUXhwekFkT1hjakRJUTFLNVNGcmRrN2xwMnNfX0dTdnEwSXowRFExOGY1NkNOalJieDFtRVhnTzFlMHQwUUZ3S1pSWXNSNERvZUtx?oc=5","date":"2025-03-03","type":"trial","source":"GlobeNewswire","summary":"JAK Inhibitors Clinical Trial Pipeline Appears Robust With - GlobeNewswire","headline":"JAK Inhibitors Clinical Trial Pipeline Appears Robust With","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBOc284aHEzZGJDSmJJYko3aG5WbXRmV0lmTkUtOWU1WlBsZnF5ZVpJVjRxRjI2N0FqTnRobFZISE1GbDh0ZXNZMTlqSFNDSWZJY0Fjd2hNNXR5SUlhZnFQMmFrV1Q3MFVqUVBFYnBUWEhBZ2pMV3ppTUdR?oc=5","date":"2024-11-25","type":"trial","source":"Wiley","summary":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia - Wiley","headline":"Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygJBVV95cUxQakpyeFFkUXVCSmx3cnNwckhOS0xXTDdPSHlMRnRpTDdTcGdtV1dDNzNhVVgxck1lN1B0MUN0RTNucXNheWJEZlJNbzRBX2t5Rndxb0R1aGlPT2V0UlZSWkxjWGZHT09WQktDRFhCRmVDd2ptUE5pdjRjMEtvLUJNbDNKRWxkLXFlMlBQa0FhSlM3WE9mN09kNlNac0pXUms5cGtMOTdWcTJNckhfT3o5aU1IOXMyay1jamZ6aV9ndTEzVHl5eWM3WGotQkRwdUpfZ1dPeUF4VkI5U09TSExYcnp6Wlo2akhUNzBRWUF5dGZXUGhEcEVIVHUzbmlza3c4eU5ENmw4Q2VReW9vNFBFeXdDUFczODFfWV9LV0lxX0t2ZXRMLUV2WkhpQXh2dmZPbUl5Uzc4WHRiUDJzNjVQRVhmeTl4OU9WZlE?oc=5","date":"2024-10-30","type":"trial","source":"Business Wire","summary":"Ajax Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis - Business Wire","headline":"Ajax Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating AJ1-11095, a First-in-Class Type II","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNVjUwVDgyTFpLZzJnaENWSDQ5LUoyeHN4R2xWdG9USWwzc2h6SUtuSmFJNFIzdXVQU1IyazRqY1dNYTBxNTQ4bkNqMWp4V2c2UDQzcldLMFVtd1plN25SaG80UWdicmViU1JkWFl0Zk5DNnpPNTdKZDdHNmo2RGwzMkhEU3l5UG1McmhLZ0RWNmt0WkU?oc=5","date":"2024-08-01","type":"pipeline","source":"BioWorld News","summary":"Ajax Therapeutics identifies new JAK2 inhibitors - BioWorld News","headline":"Ajax Therapeutics identifies new JAK2 inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNM1lFRklWa1ZiQ1hXTnd6OFVEWjlZSHJKNld6MTJ1d2gyNkFTRU1nTGdMOGhidzZpSnQwcTlDM08tTktleVl4anlhY3JyelA3aDNGN0pobTZZaTF4UXA5djI3N2FvbUhlRmpiTmNCZ1lldF96a3dIMkRXQWRXcFF4NG1aZVNwR01DUllKTA?oc=5","date":"2024-05-19","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"JAK Attack: Ajax Takes Aim at Myelofibrosis - Genetic Engineering and Biotechnology News","headline":"JAK Attack: Ajax Takes Aim at Myelofibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQZDZNUWlwMEhWQmxiQWVFel9Rd1NKZ015NlVDYkFRNzdla0dZNzJpVUlNakVWakFmeHBLQUNYUTFtdVBGUENVUkZtUW9zeUQzNXN0R1RZbDJjZjVsd2NvZjBwU0xOcDJBOWNaTlptTmE2T3ZOMjdjMVVQdmUzc01ucVR6eDhmVXRHUVZJVA?oc=5","date":"2024-05-13","type":"pipeline","source":"BioPharma Dive","summary":"Ajax, aiming for a better JAK drug, raises $95M to begin first tests - BioPharma Dive","headline":"Ajax, aiming for a better JAK drug, raises $95M to begin first tests","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNaGE1aGl1ejdVVWxYZ2hERHlRbmlwOE5LbTJwblVlUmc4Tmlqc01oNnIyR2pmd2NLTXNGRnZnSDNNZmRJY3FwY3hjVlJ0M3FlM3BleDE5cjJXQ0gzQmpxbWMxU3FIaERPUjJJVnFISnVZMXk1WnJtdjFlX1RQMGN0Z2J0RjJ0dy1EaHdhTWZTOTRYSnNMOHc2V1lsRl8?oc=5","date":"2024-05-13","type":"pipeline","source":"The Business Journals","summary":"Cambridge-NYC biotech gets $95M, prepares to enter clinic with blood cancer drug - The Business Journals","headline":"Cambridge-NYC biotech gets $95M, prepares to enter clinic with blood cancer drug","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}